51
|
Efremova MV, Naumenko VA, Spasova M, Garanina AS, Abakumov MA, Blokhina AD, Melnikov PA, Prelovskaya AO, Heidelmann M, Li ZA, Ma Z, Shchetinin IV, Golovin YI, Kireev II, Savchenko AG, Chekhonin VP, Klyachko NL, Farle M, Majouga AG, Wiedwald U. Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics. Sci Rep 2018; 8:11295. [PMID: 30050080 PMCID: PMC6062557 DOI: 10.1038/s41598-018-29618-w] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Accepted: 07/16/2018] [Indexed: 12/21/2022] Open
Abstract
High-quality, 25 nm octahedral-shaped Fe3O4 magnetite nanocrystals are epitaxially grown on 9 nm Au seed nanoparticles using a modified wet-chemical synthesis. These Fe3O4-Au Janus nanoparticles exhibit bulk-like magnetic properties. Due to their high magnetization and octahedral shape, the hybrids show superior in vitro and in vivo T2 relaxivity for magnetic resonance imaging as compared to other types of Fe3O4-Au hybrids and commercial contrast agents. The nanoparticles provide two functional surfaces for theranostic applications. For the first time, Fe3O4-Au hybrids are conjugated with two fluorescent dyes or the combination of drug and dye allowing the simultaneous tracking of the nanoparticle vehicle and the drug cargo in vitro and in vivo. The delivery to tumors and payload release are demonstrated in real time by intravital microscopy. Replacing the dyes by cell-specific molecules and drugs makes the Fe3O4-Au hybrids a unique all-in-one platform for theranostics.
Collapse
Affiliation(s)
- Maria V Efremova
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Victor A Naumenko
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Marina Spasova
- Faculty of Physics and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany
| | - Anastasiia S Garanina
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Maxim A Abakumov
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
- Department of Medical Nanobiotechnology, Russian National Research Medical University, Moscow, 117997, Russian Federation
| | - Anastasia D Blokhina
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
| | - Pavel A Melnikov
- Department of Fundamental and Applied Neurobiology, Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health and Social Development of the Russian Federation, Moscow, 119034, Russian Federation
| | | | - Markus Heidelmann
- ICAN - Interdisciplinary Center for Analytics on the Nanoscale and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany
| | - Zi-An Li
- Faculty of Physics and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany
| | - Zheng Ma
- Faculty of Physics and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany
| | - Igor V Shchetinin
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Yuri I Golovin
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
- Derzhavin Tambov State University, Nanocenter, Tambov, 392000, Russian Federation
| | - Igor I Kireev
- A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
| | - Alexander G Savchenko
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Vladimir P Chekhonin
- Department of Medical Nanobiotechnology, Russian National Research Medical University, Moscow, 117997, Russian Federation
- Department of Fundamental and Applied Neurobiology, Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health and Social Development of the Russian Federation, Moscow, 119034, Russian Federation
| | - Natalia L Klyachko
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation
| | - Michael Farle
- Faculty of Physics and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany
| | - Alexander G Majouga
- Department of Chemistry, Lomonosov Moscow State University, Moscow, 119991, Russian Federation.
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation.
- D. Mendeleev University of Chemical Technology of Russia, Moscow, 125047, Russian Federation.
| | - Ulf Wiedwald
- National University of Science and Technology «MISIS», Moscow, 119049, Russian Federation.
- Faculty of Physics and Center for Nanointegration Duisburg-Essen, University of Duisburg-Essen, Duisburg, 47057, Germany.
| |
Collapse
|
52
|
Spirou SV, Basini M, Lascialfari A, Sangregorio C, Innocenti C. Magnetic Hyperthermia and Radiation Therapy: Radiobiological Principles and Current Practice †. NANOMATERIALS 2018; 8:nano8060401. [PMID: 29865277 PMCID: PMC6027353 DOI: 10.3390/nano8060401] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/29/2018] [Revised: 05/30/2018] [Accepted: 06/01/2018] [Indexed: 02/07/2023]
Abstract
Hyperthermia, though by itself generally non-curative for cancer, can significantly increase the efficacy of radiation therapy, as demonstrated by in vitro, in vivo, and clinical results. Its limited use in the clinic is mainly due to various practical implementation difficulties, the most important being how to adequately heat the tumor, especially deep-seated ones. In this work, we first review the effects of hyperthermia on tissue, the limitations of radiation therapy and the radiobiological rationale for combining the two treatment modalities. Subsequently, we review the theory and evidence for magnetic hyperthermia that is based on magnetic nanoparticles, its advantages compared with other methods of hyperthermia, and how it can be used to overcome the problems associated with traditional techniques of hyperthermia.
Collapse
Affiliation(s)
- Spiridon V Spirou
- Department of Radiology, Sismanoglio General Hospital of Attica, Sismanogliou 1, Marousi 15126, Greece.
| | - Martina Basini
- Università degli Studi di Milano, Dipartimento di Fisica, Via Celoria 16, 20133 Milano, Italy.
| | - Alessandro Lascialfari
- Università degli Studi di Milano, Dipartimento di Fisica, Via Celoria 16, 20133 Milano, Italy.
| | - Claudio Sangregorio
- ICCOM-CNR via Madonna del Piano 10, 50019 Sesto Fiorentino, Italy.
- INSTM and Dept. Of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3, 50019 Sesto Fiorentino, Italy.
| | - Claudia Innocenti
- ICCOM-CNR via Madonna del Piano 10, 50019 Sesto Fiorentino, Italy.
- INSTM and Dept. Of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3, 50019 Sesto Fiorentino, Italy.
| |
Collapse
|
53
|
Spirou SV, Costa Lima SA, Bouziotis P, Vranješ-Djurić S, Efthimiadou EΚ, Laurenzana A, Barbosa AI, Garcia-Alonso I, Jones C, Jankovic D, Gobbo OL. Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. NANOMATERIALS (BASEL, SWITZERLAND) 2018; 8:E306. [PMID: 29734795 PMCID: PMC5977320 DOI: 10.3390/nano8050306] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 04/22/2018] [Accepted: 04/29/2018] [Indexed: 12/23/2022]
Abstract
Magnetic nanoparticle (MNP)-mediated hyperthermia (MH) coupled with radiation therapy (RT) is a novel approach that has the potential to overcome various practical difficulties encountered in cancer treatment. In this work, we present recommendations for the in vitro and in vivo testing and application of the two treatment techniques. These recommendations were developed by the members of Working Group 3 of COST Action TD 1402: Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy ("Radiomag"). The purpose of the recommendations is not to provide definitive answers and directions but, rather, to outline those tests and considerations that a researcher must address in order to perform in vitro and in vivo studies. The recommendations are divided into 5 parts: (a) in vitro evaluation of MNPs; (b) in vitro evaluation of MNP-cell interactions; (c) in vivo evaluation of the MNPs; (d) MH combined with RT; and (e) pharmacokinetic studies of MNPs. Synthesis and characterization of the MNPs, as well as RT protocols, are beyond the scope of this work.
Collapse
Affiliation(s)
- Spiridon V Spirou
- Department of Radiology, Sismanoglio General Hospital of Attica, Sismanogliou 1, Marousi 15126, Athens, Greece.
| | - Sofia A Costa Lima
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto 4050-313, Portugal.
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Aghia Paraskevi, Athens 15310, Greece.
| | - Sanja Vranješ-Djurić
- "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade 11351, Serbia.
| | - Eleni Κ Efthimiadou
- Inorganic Chemistry Laboratory, Chemistry Department, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou 15784, Greece.
- Institute of Nanoscience and Nanotechnology, NCSR Demokritos, Agia Paraskevi Attikis, Athens 15310, Greece.
| | - Anna Laurenzana
- Department of Biomedical and Clinical Science "Mario Serio", University of Florence, 50134 Firenze, Italy.
| | - Ana Isabel Barbosa
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto 4050-313, Portugal.
| | - Ignacio Garcia-Alonso
- Department of Surgery, Radiology & Ph.M. University of the Basque Country, Bilbao E48940, Spain.
| | - Carlton Jones
- NanoTherics Ltd., Studio 3, Unit 3, Silverdale Enterprise Centre Kents Lane, Newcastle under Lyme ST5 6SR, UK.
| | - Drina Jankovic
- "Vinča" Institute of Nuclear Sciences, University of Belgrade, Belgrade 11351, Serbia.
| | - Oliviero L Gobbo
- School of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, D02PN40 Dublin, Ireland.
| |
Collapse
|
54
|
Wu W, Luo L, Wang Y, Wu Q, Dai HB, Li JS, Durkan C, Wang N, Wang GX. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. Theranostics 2018; 8:3038-3058. [PMID: 29896301 PMCID: PMC5996358 DOI: 10.7150/thno.23459] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Accepted: 03/06/2018] [Indexed: 12/20/2022] Open
Abstract
Nanotechnology-based antitumor drug delivery systems, known as nanocarriers, have demonstrated their efficacy in recent years. Typically, the size of the nanocarriers is around 100 nm. It is imperative to achieve an optimum size of these nanocarriers which must be designed uniquely for each type of delivery process. For pH-responsive nanocarriers with programmable size, changes in pH (~6.5 for tumor tissue, ~5.5 for endosomes, and ~5.0 for lysosomes) may serve as an endogenous stimulus improving the safety and therapeutic efficacy of antitumor drugs. This review focuses on current advanced pH-responsive nanocarriers with programmable size changes for anticancer drug delivery. In particular, pH-responsive mechanisms for nanocarrier retention at tumor sites, size reduction for penetrating into tumor parenchyma, escaping from endo/lysosomes, and swelling or disassembly for drug release will be highlighted. Additional trends and challenges of employing these nanocarriers in future clinical applications are also addressed.
Collapse
Affiliation(s)
- Wei Wu
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| | - Li Luo
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| | - Yi Wang
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| | - Qi Wu
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| | - Han-Bin Dai
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| | - Jian-Shu Li
- College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, China
| | - Colm Durkan
- The Nanoscience Centre, University of Cambridge, Cambridge, CB3 0FF, UK
| | - Nan Wang
- The Nanoscience Centre, University of Cambridge, Cambridge, CB3 0FF, UK
| | - Gui-Xue Wang
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China
| |
Collapse
|
55
|
Abstract
Multifunctional nanoparticles with superior imaging properties and therapeutic effects have been extensively developed for the nanomedicine. However, tumor-intrinsic barriers and tumor heterogeneity have resulted in low in vivo therapeutic efficacy. The poor in vivo targeting efficiency in passive and active targeting of nanotherapeutics along with the toxicity of nanoparticles has been a major problem in nanomedicine. Recently, image-guided nanomedicine, which can deliver nanoparticles locally using non-invasive imaging and interventional oncology techniques, has been paid attention as a new opportunity of nanomedicine. This short review will discuss the existing challenges in nanomedicine and describe the prospects for future image-guided nanomedicine.
Collapse
Affiliation(s)
- Dong-Hyun Kim
- Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
- Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
| |
Collapse
|
56
|
Choi JY, Ryu J, Kim HJ, Song JW, Jeon JH, Lee DH, Oh DJ, Gweon DG, Oh WY, Yoo H, Park K, Kim JW. Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo. Am J Cancer Res 2018; 8:45-60. [PMID: 29290792 PMCID: PMC5743459 DOI: 10.7150/thno.20885] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 09/27/2017] [Indexed: 12/16/2022] Open
Abstract
Rationale: Atherosclerotic plaque is a chronic inflammatory disorder involving lipid accumulation within arterial walls. In particular, macrophages mediate plaque progression and rupture. While PPARγ agonist is known to have favorable pleiotropic effects on atherogenesis, its clinical application has been very limited due to undesirable systemic effects. We hypothesized that the specific delivery of a PPARγ agonist to inflamed plaques could reduce plaque burden and inflammation without systemic adverse effects. Methods: Herein, we newly developed a macrophage mannose receptor (MMR)-targeted biocompatible nanocarrier loaded with lobeglitazone (MMR-Lobe), which is able to specifically activate PPARγ pathways within inflamed high-risk plaques, and investigated its anti-atherogenic and anti-inflammatory effects both in in vitro and in vivo experiments. Results: MMR-Lobe had a high affinity to macrophage foam cells, and it could efficiently promote cholesterol efflux via LXRα-, ABCA1, and ABCG1 dependent pathways, and inhibit plaque protease expression. Using in vivo serial optical imaging of carotid artery, MMR-Lobe markedly reduced both plaque burden and inflammation in atherogenic mice without undesirable systemic effects. Comprehensive analysis of en face aorta by ex vivo imaging and immunostaining well corroborated the in vivo findings. Conclusion: MMR-Lobe was able to activate PPARγ pathways within high-risk plaques and effectively reduce both plaque burden and inflammation. This novel targetable PPARγ activation in macrophages could be a promising therapeutic strategy for high-risk plaques.
Collapse
|
57
|
Xiang D, Shigdar S, Bean AG, Bruce M, Yang W, Mathesh M, Wang T, Yin W, Tran PHL, Shamaileh HA, Barrero RA, Zhang PZ, Li Y, Kong L, Liu K, Zhou SF, Hou Y, He A, Duan W. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Am J Cancer Res 2017; 7:4071-4086. [PMID: 29158811 PMCID: PMC5694998 DOI: 10.7150/thno.20168] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 06/25/2017] [Indexed: 02/06/2023] Open
Abstract
Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold lower frequency of CSC and a prolonged longer tumourigenic latency compared with those receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug resistance in solid tumours.
Collapse
|